1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J].CA Cancer J Clin,2019,69(1):7-34. 2 Torre LA,Siegel RL,Jemal A.Lung cancer statistics[J].Adv Exp Med,Biol,2016,893:1-19. 3 Kim KH,Park TY,Lee JY,et al.Prognostic significance of initial platelet counts and fibrinogen level in advanced non-small cell lung cancer[J].J Korean Med Sci,2014,29(4):507-511. 4 Zhu YW,Feng TB,Zhou XJ,et al.Routine hemostasis and hemogram parameters:valuable assessments for coagulation disorder and chemotherapy in cancer patients[J].Chin Med J(Engl),2016,129(15):1772-1777. 5 王若楠,高云芬,解俊敏.银杏叶提取物注射液对肺癌化疗患者血液高凝状态的影响[J].中外医学研究,2016,14(6):43-45. 6 蒋丽君,张伟,钮晖,等.379例晚期恶性肿瘤患者凝血功能的改变及其临床意义[J].宁夏医科大学学报,2019,41(7):681-684. 7 Zhu LR,Li J,Chen P,et al.Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients[J].Clin Transl Oncol,2016,18(2):178-188. 8 Saccullo G,Malato A,Raso S,et al.Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia:the use of fixed sub-therapeutic doses of low-molecular weight heparin[J].Am J Hematol,2012,87(4):388-391. 9 王静,张侠.恶性肿瘤患者高凝状态的危险因素、发生机制及实验室检测[J].检验医学与临床,2015,12(15):2284-2287. 10 吴晓谦,林群力.库欣综合征及肥胖症患者凝血功能的改变及影响因素[J].中国药物与临床,2019,19(4):580-582. 11 椰慧楠,王哲,汪忠森.低分子肝素对恶性肿瘤患者血液高凝状态以及生存率的影响[J].疑难病杂志,2016,15(3):273-275. 12 Zhang XJ,Liu YG,Shi XJ,et al.The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer:A meta-analysis[J].Int J Surg,2015,21:84-91. 13 Yang L,Dong H,Li Z,et al.Correlation between circulating tumor cells and D-D and platelet in patients with pulmonary malignancies[J].Oncol Lett,2018,15(2):2169-2172. 14 Zhao J,Zhao M,Jin B,et al.Tumor response and survival in patients with advanced non-small-cell lung cancer:the predictive value of chemotherapy-induced changes in fibrinogen[J].BMC Cancer,2012,12:330. 15 Li W,Tang Y,Song Y,et al.Prognostic role of pretreatment Plasma D-dimer in patients with solid tumors:a systematic review and meta-analysis[J].Cell Physiol Biochem,2018,45(4):1663-1676. 16 胡建军.肺癌患者血中D-二聚体和纤维蛋白原改变在肺癌中的临床意义[J].中国现代医生,2011,49(10):51-52. 17 李佩章,王英,黄玲莎,等.血浆D-二聚体和纤维蛋白原改变在肺癌中的临床意义[J].临床肺科杂志,2013,18(4):692-693. 18 Blom JW,Doggen CJ,Osanto S,et al.Malignancies,prothrombotic mutations,and the risk of venous thrombosis[J].JAMA,2005,293(6):715-725. 19 Kessler CM.The link between cancer and venous thromboembolism:a review[J].Am J Clin Oncol,2009,32(4 Suppl):3-7. 20 Khorana AA,Kuderer NM,Culakova E,et al.Development and validation of a predictive model for chemotherapy-associated thrombosis[J].Blood,2008,111(10):4902-4907. 21 Tas F,Kilic L,Serilmez M,et al.Clinical and prognostic significance of coagulation assays in lung cancer[J].Respir Med,2012,44(3):285-292. 22 Li XH,Wang XP,Gu WS,et al.Clinical significance of preoperative thrombin time in patients with esophageal squamous cell carcinoma following surgical resection[J].PLoS One,2015,10(10):e0140323. |